Physician profile
Brian T Woolf
NPI 1760577605
$19,334.22
in general payments reported to CMS, 2019-2025
23 companies · $1,695 in 2025
The $1,695 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $2,456 · 2021: $2,897 · 2022: $5,350 · 2023: $4,066 · 2024: $2,553 · 2025: $1,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,356 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,300 · Travel and Lodging: $1,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,355.86 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,300.00 |
| Travel and Lodging | $1,658.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $10,349.28 | 2019-2025 | Dailies Total1, Precision 1, Air Optix Color |
| Carl Zeiss Meditec USA, INC. | $2,055.29 | 2023 | Visumax |
| Coopervision INC. | $1,617.08 | 2022-2025 | Misight Contact Lens, Myday Contact Lens |
| Biotissue Holdings INC. | $1,594.23 | 2021-2025 | |
| Lumenis Be INC | $550.31 | 2024 | Optilight |
| Johnson & Johnson Vision Care, INC. | $480.27 | 2020-2024 | Acuvue |
| Sun Pharmaceutical Industries INC. | $423.21 | 2022-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $385.03 | 2024-2025 | Xdemvy |
| Notal Vision, INC. | $302.24 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $295.17 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $256.03 | 2022-2025 | Infuse, Miebo, Xiidra |
| Dompe US, INC. | $234.40 | 2021-2025 | Oxervate |
| Oyster Point Pharma, INC. | $194.40 | 2022-2025 | Tyrvaya, Ryzumvi |
| Lkc Technologies, INC. | $157.05 | 2024 | |
| Sight Sciences, INC. | $140.54 | 2022-2024 | Tearcare System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $81.96 | 2022-2023 | Uplizna |
| Allergan, INC. | $66.99 | 2020-2022 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Abb Con-Cise Optical Group LLC | $34.28 | 2020 | |
| Oasis Medical, INC. | $22.12 | 2020-2021 | |
| Abbvie INC. | $21.84 | 2022 | |
| Kala Pharmaceuticals, INC. | $20.26 | 2022 | |
| Maculogix, INC. | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Woolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.